STOCK TITAN

TransMedics Group (TMDX) Stock News

TMDX NASDAQ

TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.

Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.

Rhea-AI Summary

TransMedics (TMDX) reported third-quarter 2026 revenue of $203.0 million, up 41% year over year, and raised its full-year revenue outlook. Organic revenue growth was 35%. Product revenue rose 29% to $113.4 million, while service revenue increased 60% to $89.6 million. Operating income increased 21% to $28.1 million, but net income fell to $17.1 million from $24.3 million. Diluted earnings per share declined 30% to $0.46.

Full-year revenue guidance increased to $750-$760 million excluding PAD Aviation, versus $737-$757 million previously. Including approximately $14 million from PAD Aviation, guidance is $764-$774 million. In October, FDA approvals allowed ENHANCE Heart Part B and DENOVO Lung trials to proceed, and a continued access protocol permitted 90 additional heart-trial patients. TransMedics also won its first European transplant logistics tender in Italy. Cash totaled $493.0 million at September 30.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.92%
Tags
-
Rhea-AI Summary

TransMedics (Nasdaq: TMDX) granted stock options and restricted stock units to nine employees on October 28, 2026, as employment inducements.

The awards cover options to purchase 71,815 shares at an exercise price of $66.90 per share and 47,924 restricted stock units (RSUs). Chief Financial Officer Fernando Araujo received options covering 34,419 shares and 22,969 RSUs. The Compensation Committee approved the grants under the Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Options have a 10-year term, with 25% vesting after the first year of employment and the remainder monthly over the next three years. RSUs vest 25% on each of the first four employment anniversaries. All vesting requires continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
Rhea-AI Summary

TransMedics Group (TMDX) announced that management is scheduled to participate in fireside chats at three upcoming investor conferences. The events are Stifel in New York on November 10, 2026, at 10:40 a.m. EST; Jefferies in London on November 17 at 7:00 a.m. EST; and Piper Sandler in New York on December 1 at 4:30 p.m. EST. Live and archived webcasts will be available on the company's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
conferences
Rhea-AI Summary

TransMedics Group (TMDX) will release its third-quarter 2026 financial results after market close on November 5, 2026. Management will host a corresponding conference call at 4:30 p.m. ET / 1:30 p.m. PT. A live and archived webcast will be available in the Investors section of the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
earnings date
-
Rhea-AI Summary

TransMedics (TMDX) appointed Fernando Araujo as Chief Financial Officer effective September 21, 2026, and reiterated its full-year 2026 revenue outlook.

Araujo has more than 20 years of public-company finance experience at GE HealthCare, General Electric, and 3M, including serving as CFO of GE HealthCare's $16 billion Advanced Imaging Solutions segment and leading corporate finance FP&A and finance transformation. He succeeds Gerardo Hernandez, who will become Commercial Strategic Advisor, LATAM to lead TransMedics' expansion in Latin America.

TransMedics reaffirmed 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth, excluding any revenue from its recent strategic investment in PAD Aviation Service GmbH. The company expects to revisit this outlook with third quarter 2026 results.

Management will participate in fireside chats at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, and the Baird 2026 Global Healthcare Conference on September 15, 2026, with webcasts available in the investors section of its website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
Rhea-AI Summary

TransMedics (Nasdaq: TMDX) announced participation in two New York investor conferences in September 2026. Management will join a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 3:20 p.m. EST and at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, at 9:40 a.m. EST. A live and archived webcast of the fireside chat and the company’s standard investor presentation will be available in the Investors section of the TransMedics website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.10%
Tags
none
Rhea-AI Summary

TransMedics (Nasdaq:TMDX) reported second quarter 2026 revenue of $189.9 million, up 21% year over year, driven by higher utilization of its Organ Care System, especially liver and heart via the National OCS Program, and growth in logistics services. Product revenue rose 16% to $111.2 million and service revenue increased 29% to $78.8 million.

Gross margin was 60% versus 61% a year ago. Operating expenses rose to $89.5 million from $60.0 million, reflecting investment in OCS Kidney, Gen 3.0, clinical programs and infrastructure. Income from operations declined to $23.7 million from $36.6 million, while net income fell to $14.7 million, or $0.41 per diluted share, from $34.9 million, or $0.92 per diluted share. Cash stood at $472.7 million on June 30, 2026. The company raised the low end of its 2026 revenue outlook to $737–$757 million, implying 22%–25% growth versus 2025, excluding PAD Aviation revenue. On July 1, 2026, TransMedics completed a strategic investment in PAD Aviation to start building a dedicated organ transport air logistics network in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
-
Rhea-AI Summary

TransMedics (Nasdaq: TMDX) reported that on July 29, 2026 it granted non-qualified stock options for an aggregate 18,762 shares and 12,414 restricted stock units to nine new employees as material inducement awards under its Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

The options have a 10-year term, a per-share exercise price of $78.00, and vest 25% after one year with the balance vesting monthly over three years, subject to continued service. RSUs vest 25% on each of the first four anniversaries of employment, also subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
Rhea-AI Summary

TransMedics (Nasdaq: TMDX) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The TransMedics management team is scheduled to present at 2:00 p.m. ET / 1:00 p.m. CT. A live and archived webcast of the fireside chat, along with the company’s standard investor presentation, will be accessible via the Investors section of the TransMedics website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
Rhea-AI Summary

TransMedics (Nasdaq:TMDX) will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT with phone and webcast access for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
earnings date

FAQ

What is the current stock price of TransMedics Group (TMDX)?

TransMedics Group (TMDX) last closed at $93.91.

What is the market cap of TransMedics Group (TMDX)?

The market cap of TransMedics Group (TMDX) is approximately $3.3B.